Protara Therapeutics(US:TARA) Seeking Alpha·2026-01-15 05:25Core Viewpoint - Protara Therapeutics is a clinical stage biotechnology company focused on developing transformative therapies for rare cancer diseases, with a strong emphasis on oncology and rare diseases [2]. Oncology Focus - The company has two late-stage development programs targeting non-muscle invasive bladder cancer, specifically in BCG-Unresponsive and BCG-Naïve patients [2][4]. - The ADVANCED-2 study is a significant registrational study for BCG-Unresponsive patients with carcinoma in situ, with expectations to complete enrollment before the end of 2026 [4]. Rare Disease Programs - Protara is developing two products in clinical development for rare diseases: - IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral support, currently in Phase III with a pharmacokinetic-based endpoint [3]. - TARA-002, targeting lymphatic malformations for macrocystic and mixed cystic lesions [3]. Company Ambition - Despite its size, Protara demonstrates significant ambition through its diverse portfolio of late-stage development programs in both oncology and rare diseases [4].